APIXABAN in the Prevention of Stroke and Systemic Embolism in Patients With Atrial Fibrillation in Real-Life Setting in France SNIIRAM Study

Active, not recruiting

Phase N/A Results N/A

Eligibility Criteria

Inclusion Criteria

- Patient meeting inclusion criteria of the French Système national d'information inter-régimes de l'assurance maladie (SNIIR-AM)/Programme de médicalisation des systèmes d'information (PMSI) claim databases (Patient insured by the French national health insurance general scheme stricto sensu (apart from local mutualist sections)
- Patients with at least one reimbursement of AC treatment (acenocoumarol, warfarine and fluidione for VKA treatments, apixaban, dabigatran or rivaroxaban for New oral anticoagulants (NOACs)) treatments during the inclusion period
- Patients initiated with a new AC treatment during the inclusion period, either AC naive or not
- Patients aged 18 or older at their first anticoagulant initiation during the inclusion period
- Patient diagnosed with non-valvular Atrial fibrillation (AF)